Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Time to Sell?

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) traded down 2.1% during trading on Friday . The stock traded as low as C$1.85 and last traded at C$1.89. 80,575 shares changed hands during trading, a decline of 40% from the average session volume of 135,165 shares. The stock had previously closed at C$1.93.

Cardiol Therapeutics Stock Down 2.1 %

The stock has a market capitalization of C$132.07 million, a price-to-earnings ratio of -4.30 and a beta of 0.70. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The business has a fifty day moving average of C$2.44 and a 200 day moving average of C$2.75.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.